Moneycontrol PRO
you are here: HomeNewsBusiness

ICEA urges Centre to extend timeline of PLI scheme by a year

In its letter to the Centre, the ICEA proposed that the current fiscal (FY21) be considered as "zero year" with no incremental incentive for production to make up for disruptions due to the pandemic.

March 29, 2021 / 09:12 AM IST
The combined incentive scheme package for the first year is Rs 5,334 crore. (Representative image)

The combined incentive scheme package for the first year is Rs 5,334 crore. (Representative image)

Phone manufacturers have approached the government for a year's extension of the five-year production-linked incentive (PLI) scheme due to the coronavirus pandemic.

This comes as, of the 16 companies given PLI, South Korean maker Samsung was the only one able to meet the output goals for the first year ending March 31, The Economic Times reported.

In its letter to the Centre, the India Cellular & Electronics Association (ICEA) proposed that the current fiscal (FY21) be considered as "zero year" or "year of preparation" with no incremental incentive for production to make up for disruptions due to the pandemic, the report said.

Moneycontrol could not independently verify the report.

As per the letter, dated March 4, incentives should begin from FY22 and end in FY26, instead of FY25, "with no other change in scheme, keeping the yearly expenditure envelope unchanged."

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

It also suggested that investments made in FY21 and FY22 combined to be considered as the first-year targets.

The letter also noted that any company which has completed the target "due to ability to exploit existing facilities, production lines, or having long-established presence in India,” should be given the incentives as per the existing scheme. The combined incentive scheme package for the first year is Rs 5,334 crore.

So far, only Samsung has met its production and revenue targets for the first year. The other 15 companies are Ascent, AT&S, Bhagwati, Dixon, Hon Hai, Lava, Neolync, Optiemus, Pegatron, Rising Stars, Sahasra, UTL, Visicon, Walsin, and Wistron.

Reasons cited for inability to meet targets include the lockdowns, short span for expansion (six months), shortage of chipsets, and travel constraints leading to unavailability of technical consultants, etc.

The ICEA also noted that there was 97 percent supply cuts “in certain cases" and pointed out that incremental investments in the current fiscal have “already exceeded Rs 1,300 crore,” besides the creation of 22,000 new jobs, and shifting of capacities to India from abroad.

It added that while short of the industry's collective first-year PLI targets, incremental production worth Rs 35,000 crore has already been achieved.

Moneycontrol News
first published: Mar 29, 2021 09:12 am